ArticleFrontiers in endocrinology2025
Glucose Levels in At-risk Newborns (GLEAN): a prospective cohort study on glucose profiles in infants at risk of hypoglycemia.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To describe glucose patterns in at-risk infants, determine the incidence of hypoglycemia across different risk groups, and evaluate the impact of combined risk factors on odds of developing hypoglycemia. Study design: This prospective cohort study was conducted at KK Women's and Children's Hospital from 16 December 2019 to 16 March 2020, during which 2,564 babies were born. Of these, 701 were identified as at-risk of hypoglycemia based on predefined clinical criteria: infants of diabetic mothers (IDM), term infants with birth weight >4000 g or <2600 g, preterm infants, and infants of obese mothers (IOM). Risk group classification was refined using INTERGROWTH-21 Results: Mean glucose levels stabilized between 3.8 and 4.0 mmol/L by 24 hours. The highest incidence of hypoglycemia was observed in single risk factor SGA infants (22.6%), followed by IOM (16%), a group less studied in hypoglycemia risk assessments. This was comparable to the incidence seen in IDM (13.0%). In contrast, single risk factor LGA infants exhibited the lowest incidence of hypoglycemia (6.2%). Infants with combined risk factors had a higher incidence of hypoglycemia compared to those with a single risk factor (18.5% vs 15.9%) and showed higher odds of hypoglycemia compared to those with a single risk factor (OR 2.47; 95% CI: 0.98-6.08, p = 0.049). Conclusions: Glucose trajectories and hypoglycemia risks differ across clinically defined at-risk groups, underscoring the importance of targeted screening and management protocols. Stratifying infants by single and combined risk factors provided additional insight that may support future refinements to neonatal hypoglycemia clinical guidelines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.